NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Latin American Real-world Study in Acute Leukemia

CompletedN/A

Sponsor: Pfizer

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia

Countries: Argentina, Brazil, Chile, Colombia

The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin American countries.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients ≥18 years old at diagnosis
* Confirmed diagnosis of relapsed/refractory B-cell ALL or de novo AML diagnosed between 01 January 2015 and 31 December 2019
* At least 1 line of treatment for R/R B-cell ALL or de novo AML within the study period

Exclusion Criteria:

* Patients with no medical chart available
* Patients with unreliable data as per investigator's opinion (e.g. excessive missing data or inconsistence data)
* Patients that have participated in any interventional clinical trial for relapsed/refractory B-cell ALL or AML at any moment
* Patients with secondary AML
* Patients with any concomitant primary malignancy
* Patients with acute promyelocytic leukemia (APL)

Locations (14)

La Plata, Buenos Aires, Argentina
Pilar, Buenos Aires, Argentina
Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
Córdoba, Argentina
Córdoba, Argentina
Salvador, Estado de Bahia, Brazil
Jaú, SAO Paulo / Brazil, Brazil
Rio de Janeiro, Brazil
São Paulo, Brazil
São Paulo, Brazil
São Paulo, Brazil
Concepción, Chile
Bogotá, Colombia
Montería, Colombia